Introduction
============

Chronic kidney disease is a major global health problem with an increasing prevalence ([@B88]; [@B9]; [@B23]). By 2040, it is estimated that CKD will have become the fifth leading cause of death ([@B48]). This increasing CKD burden is driven in part by aging population structure (CKD is ∼8x more common in adults \> 70 years old compared to persons \< 40 years of age) ([@B9]; [@B23]). Diabetes and hypertension are common risk factors for kidney damage ([@B75]) and are therefore major contributors to the increased CKD prevalence ([@B9]).

There is a marked gender imbalance in CKD with a higher incidence (11.0 vs. 9.6 per 1,000 person-years) and higher prevalence (16.0% vs. 12.4%) in women ([@B9]; [@B23]). Nevertheless, women have a lower risk of CKD progression and men are more likely to develop ESRD ([@B123]).

Chronic kidney disease is a complex heterogeneous disease, with contributions from both genomic and environmental factors. CKD heritability has been estimated to be high (30--75%) ([@B129]; [@B110]; [@B122]). CKD can be identified by well-established clinical biomarkers such as SCr levels, eGFR, albuminuria, or UACR ([@B17],[@B18]). Unfortunately, these clinical biomarkers are limited in their utility to predict individual risk of CKD or likelihood for later progression to ESRD. Major efforts have been made to understand the heritability in CKD but the causal pathways remain incompletely understood. Four major approaches have been proposed to uncover the missing heritability; exploration of rare variants, increased samples sizes, study of molecular factors not involving variants in the DNA sequence and consideration of whether family studies overestimated heritability risk ([@B13]). In CKD, meta-analyses of GWAS have provided a useful and relatively inexpensive strategy to increase the statistical power by combining data summaries from different individual GWAS, helping to attenuate the issue of small sample size and identifying many genetic loci associated with CKD and/or kidney function traits ([@B81], [@B82]; [@B25]; [@B12]; [@B111]; [@B113]; [@B55]). Rare variants in *UMOD, SHROOM3*, solute carriers, and E3 ubiquitin ligases have also been associated with CKD, eGFR or SCr ([@B83]; [@B141]; [@B118]). However, these genetic markers do not account for all the susceptibility to CKD, therefore other factors must be contributing to the missing heritability. Part of the missing heritability may correspond to genetic interactions (epistasis), rather than to missing variants ([@B170]). Telomere length is a biological factor that has been associated with CKD prevalence and/or CKD progression in a small number of studies ([@B3]). Structural variants, such as CNVs, insertions, deletions, inversions and translocations are, in general, poorly covered in commercial arrays and may explain part of the missing heritability ([@B97]). Mitochondrial proteins, encoded by nuclear genes, and specific mtDNA encoded genes have also been associated with CKD ([@B136]). The sex chromosomes, often excluded from GWAS studies, may help explain gender imbalances in CKD.

In this review, we outline some recent findings on molecular biomarkers for CKD (telomeres, CNVs, mtDNA variants, X and Y chromosomes) that typically have received less attention than single nucleotide polymorphisms (SNPs) present on, or imputed from, GWAS arrays. These less commonly studied biomarkers may be part of the "missing heritability" for CKD.

Telomeres and CKD
-----------------

Telomeres are specialized nucleoprotein complexes that help protect the ends of linear chromosomes ([@B131]). There are inter-individual and intra-individual differences in the length of telomeres. Shorter telomere length has been associated with multi-system diseases, early life stressors, increasing chronological age and all-cause mortality ([@B40]; [@B37]; [@B38]; [@B96]; [@B159]; [@B161]) ([Figure 1](#F1){ref-type="fig"}). The majority of studies have analyzed relative telomere length in peripheral blood leukocytes, but telomere length differs between tissues within a single individual, with greater heterogeneity in telomere length evident in older people ([@B16]; [@B40]). Telomere length has a reported heritability of 28--82%, however, not all genetic factors ([@B15]; [@B31]) or environmental influences on telomere length are known ([@B35]; [@B44]; [@B53]; [@B93]). Meta-analysis of telomere length may help confirm discovery associations across multiple collections, however, this is challenging with different wet-lab techniques (such as time at sample collection, storage and processing of biological material, absolute compared to relative telomere length evaluation, platform employed) and *in silico* analyses (such as normalization, controls, covariates, association, and correction tools) having significant effects on the reported measurements. There is also limited traditional epidemiological evidence exploring the mechanistic basis or causality of reported associations.
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Nonetheless, there is evidence that telomere length is associated with disease states, particularly age-related diseases, beyond the most commonly studied cancers ([@B124]; [@B69]). Conflicting reports have been published for the association of telomere length with renal disease, however, most publications, albeit in relatively small sample sizes with modest significance values, report that shorter telomere length is associated with renal dysfunction. Shorter telomeres have been reported as associated with progression of CKD (defined as a doubling of baseline SCr and/or ESRD), in the MMKD (*n* = 59 patients had confirmed CKD progression) and CRISIS (*n* = 105 patients had confirmed CKD progression) studies, with the effect size strengthened by smoking and the presence of diabetes ([@B120]). Telomere shortening has been associated with IgAN in 177 patients, but not in 30 patients with DKD or 30 patients with FSGS compared to 83 controls ([@B94]). A study examining DNA from peripheral blood and urine in 15 patients with IgAN showed shorter telomere length correlated with declining renal function ([@B143]). Multiple studies have been performed for DKD, with the majority linking shorter telomere length to the development and progression of kidney disease in people with both type 1 ([@B5], 273 patients; [@B50], 176 patients, 21 progressed) and type 2 diabetes ([@B147], 168 patients; [@B157], 17 patients; [@B148], 501 patients; [@B61], 691 patients). Shorter telomere length is associated with diabetic complications ([@B148]) and all-cause mortality ([@B5]). The Heart and Soul Study is a longitudinal cohort of individuals with stable coronary heart disease; shorter telomere length at baseline and more rapid telomere shortening over 5 years were associated with reduced kidney function, but these changes were not significant when accounting for age ([@B8]). It is noteworthy that the largest study published considered less than 1,000 individuals ([@B148]), which provides limited power to draw robust conclusions in this era of mega-consortia studying the genetics of CKD.

Premature telomere shortening is associated with duration of dialysis treatment in terms of months to years ([@B14]). A cross-sectional study of 175 hemodialysis patients reported shorter telomere length in men with CKD, despite women having an older average age in this cohort; association of shorter telomeres was also observed with increasing age and male sex ([@B21]). Shorter telomeres were associated with CKD in 203 Japanese hemodialysis patients compared to 203 age and sex-matched controls without CKD, with shorter telomeres also associated with new onset cardiovascular events ([@B67]). A less reactive immune system is associated with healthy aging in the general population and ESRD enhances premature immunological aging with shorter telomeres observed in 137 patients with ESRD compared to 144 individuals without kidney disease ([@B11]).

Histologically normal and abnormal human kidney tissue samples from 24 individuals highlighted age-related shorter telomere length with telomeres typically shorter in the cortex than in the medulla ([@B103]). Premature senescence is an important feature of renal fibrosis that accelerates when cells are exposed to stressful environments such as more ROS and higher glucose ([@B157]; [@B20]; [@B19]). Increasing age and sex related telomere shortening is observed in kidneys, with shorter telomeres observed in male rats ([@B30]). Multiple animal models of kidney disease show telomere shortening associated with renal dysfunction, however, a careful experimental design is required for accurate telomere measurement ([@B64]). Exploring renal ischemia/reperfusion injury in wild-type and telomerase deficient mice also suggests that shorter telomeres impair recovery from acute kidney injury ([@B160]; [@B138]; [@B29]). Severe renal failure induces telomere shortening ([@B163]) with rapid telomere loss observed during kidney transplantation in a rat model of chronic rejection ([@B71]). Tucker and colleagues demonstrated that high-intensity interval training was beneficial protecting against telomere erosion in a rat model of CKD ([@B154]).

Large-scale studies using carefully collected biological samples with harmonized phenotypes and analysis protocols will help determine the true association of telomere length for CKD. Potential therapies exist to minimize premature telomere shortening ([@B153]; [@B125]), but further work is needed to define the mechanistic links between telomere length and kidney function.

Copy Number Variation and Larger Chromosomal Re-arrangements Association With CKD
---------------------------------------------------------------------------------

Copy number variants are genetic structural variants which involve DNA regions being deleted or duplicated. This can occur throughout the genome affecting stretches of DNA ranging from kilo- to mega-base pairs in length and can result in abnormal gene amplification ([@B150]; [@B126]). CNVs can be both inherited and arise *de novo*, and are increasingly being recognized as a significant source of genetic variation relating to both population diversity and disease, including renal diseases ([@B126]), neuropsychiatric diseases ([@B89]), and cancer ([@B90]).

There is often uncertainty about the genetic basis of CKD in pediatric patients, but recent studies have indicated that chromosomal microarrays have the potential to partly address this. [@B156] assessed 419 children enrolled in the CKD in children (CKiD) study alongside 21,575 children and adults who had undergone microarray genotyping for non-CKD studies. CNV disorders were identified in 31 children with CKD and 10 known pathogenic genomic disorders were detected including *HNF1B* deletion at 17q12. A further 12 pathogenic genomic imbalances were identified using this technique, distributed evenly among patients diagnosed with congenital and non-congenital forms of CKD. Overall, large gene-altering CNVs were more common in the CKiD population compared with the controls (38 vs. 23%), but the specific genetic alterations identified in several of the individuals would require personalized recommendations in future healthcare.

Copy number variants have been linked to CAKUT ([@B128]; [@B22]; [@B10]; [@B134]). In a study by [@B22], DNA from 178 Australian children who presented with any abnormality associated with CAKUT was screened using SNP arrays. In total, CNVs were identified in 18 children, of which 11 children presented with genomic disorders of unknown significance. Of these 11 participants, four were reported as having duplications of 1q23.1, 4p16.1, 7q33, and 8q13.2q13.3 regions, containing genes *NEPH1, SLC2A9, AKR1B1*, and *EYA1*, respectively. Each of these genes have previously been associated with renal abnormalities.

In an investigation undertaken by [@B134], seven children with CAKUT were assessed from three unrelated families using array comparative genomics hybridization. Of these participants, one reportedly had ureterovesical junction obstruction and a 1.4 Mb deletion at 17q12, containing two genes, *HNF1B*, which has been previously associated with CAKUT, and ACACA ([@B151]; [@B22]).

A recent study published by [@B10], suggested whole exome sequencing (WES) as a viable method to detect CNVs in individuals with CAKUT. These investigators performed WES in 112 individuals from 62 families, to identify SNVs and CNVs in 35 genes previously related to CAKUT. They identified a *de novo* triplication in one family at 22q11, and overall, 6.5% of the individuals assessed in this investigation were shown to have pathogenic CNVs.

Posterior urethral valves are one of the most common causes of CKD in children. [@B46] assessed the phenotypic effects of and relationship between renal outcomes and CNVs in 45 boys with PUV. In total, 13 CNVs were identified in 12 boys, two of which, at positions 3p25.1p25.2 and 17p12, were pathogenic in nature. Additionally, those CNVs identified which were \> 100 kb in size, were significantly associated with earlier onset of renal failure in children with PUV.

Nephronophthisis (NPH) is a Mendelian genetic disease, which often leads to ESRD by around 13 years of age. [@B137] sought to investigate the prevalence of NPH in adult-onset ESRD, through assessment of the CNVs in the *NPHP1* gene (\>90 kb) because a homozygous full gene deletion is a prominent cause of NPH. These investigators assessed 5,606 adult renal transplant recipients, 26 of whom showed evidence of the homozygous *NPHP1* deletion, compared to none of the 3,311 controls. Despite this, only 12% of the patients with the homozygous *NPHP1* gene deletion were clinically diagnosed with NPH.

Copy number variants have also been investigated in association with IgAN, which is the most common cause of primary glomerulonephritis ([@B2]). The multi-allelic CNV in the defensin alpha 1 and alpha 3 gene locus (*DEFA1A3*) was assessed in two independent IgAN cohorts of Chinese Han individuals ([@B2]). This locus can present as tandem repeats of a 19kb DNA stretch, containing one copy of either *DEFA1* or *DEFA3*, and several bi-allelic polymorphisms. The protein products of *DEFA1A3*, human neutrophil peptides 1--3, are abundant neutrophil granule proteins and function in the regulation of both the complement system and pro-inflammatory cytokine production. Each of these have been previously linked with IgAN.

Evaluation of the presence of CNVs yields potentially useful clinical information, especially for pediatric individuals with CKD.

Copy number variants in the human genome are likely to contribute to healthy development, but have additionally been linked to several human diseases ([@B126]; [@B90]; [@B89]). The molecular mechanisms that trigger the formation of CNVs are not fully understood, but recurrent CNVs with common breakpoints reportedly arise through unequal meiotic or non-allelic homologous recombination ([@B4]). Recent evidence has suggested that *de novo* and non-recurrent CNVs may develop following either replicative errors, chromosome shattering or chromothripsis ([@B78]; [@B4]; [@B108]).

Replication stress occurring during DNA replication has been linked to the collapse of the DNA replication fork and creation of a single-ended double strand break ([@B4]). It has been considered that this could result in a high frequency of *de novo* CNVs. Both the fork collapse and strand break could result in the activation of damage checkpoint and repair pathways to correctly reactivate replication, thus preventing the creation of structural variants. However, CNVs are understood to be created if this reactivation occurs in an incorrect location using a template switch, or when an incorrect repair occurs, which joins two distant DNA breaks and causes a large deletion ([@B4]). Any present mutations which inhibit the ability of the cell to accurately respond to a collapsed fork, are thought to ultimately increase the formation of CNVs ([@B4]).

Single Nucleotide Polymorphisms and Chronic Kidney Disease
----------------------------------------------------------

In the last decade, GWAS have become essential for investigating the genetic contribution to CKD, with over 50 germline genetic loci identified as biomarkers of kidney disease risk or associated with SCr, cystatin-C and/or microalbuminuria ([@B17]). The *UMOD* gene, coding for uromodulin, the most abundant urinary protein ([@B39]), is the gene with most of the consistently replicated genetic associations ([@B17]). Several common *UMOD* variants (rs12917707, rs4293393, rs11864909, rs13329952) are associated with both CKD and eGFR ([@B81], [@B82]; [@B59]; [@B112], [@B113]). More recently, the higher frequency in ESRD of another common *UMOD* variant (rs13333226), has been confirmed in 638 Chinese patients with ESRD and 366 controls ([@B28]). Several common variants in the myosin heavy chain type II isoform A (*MYH9*) gene have been associated with non-diabetic ESRD in African Americans ([@B73]; [@B80]; [@B25]). Common variants in *APOL1* are also associated with non-diabetic ESRD ([@B54]; [@B155]; [@B49]). Common variants in *ELMO1* gene have been associated with DKD and its progression to ESRD in several populations, although in this case with less consistency ([@B132]; [@B87]; [@B115],[@B116]; [@B107]). A more recent meta-analysis of GWAS, including data from 133,413 individuals and subsequently replicated in 42,166 individuals, identified 24 new loci associated with eGFR (*BCAS1, AP5B1, A1CF, PTPRO, UNCX, NFKB1, TP53INP2, KCNQ1, CACNA1S, WNT7A, TSPAN9, IGFBP5, KBTBD2, RNF32, SYPL2, SDCCAG8, ETV5, DPEP1, LRP2, SIPA1L3, INHBC, ZNF204, SKIL*, and *NFATC1*) ([@B113]). The *trans*-ethnic meta-analysis showed that 12 loci had fully consistent effect direction on eGFR across European, Asian and African individuals (*SDCCAG8, LRP2, IGFBP5, SKIL, UNCX, KBTBD2, A1CF, KCNQ1, AP5B1, PTPRO, TP53INP2*, and *BCAS1*). Regarding other measures of kidney function, a variant rs1801239 in the *CUBN* gene was proposed as a predictor of UACR and microalbuminuria in a meta-analysis of 63,153 individuals of European ancestry ([@B12]), and another variant in the same gene, rs10795433, has been associated with UACR in 5,825 individuals of European ancestry with diabetes compared to 46,061 without diabetes ([@B149]). A recent discovery GWAS of UACR in 382,500 unrelated European participants of the UK Biobank, a population-based cohort, reported 33 common variants, 20 of them sharing a consistent direction of effect with the study by [@B149], including *CUBN, HOTTIP, LOC101927609, NR3C2, ARL15, SHROOM3, MAPKBP1, ICA1L, SNX17, LRMDA, SBF2, SPATA5L1, FUT1/IZUMO1* genes and additional variants in chromosomes 1, 2, 7, 14, and 15: rs10157710, rs12032996, rs1276720, rs17158386, rs2023844, rs2472297, rs4410790, rs6535594, rs702634, rs7654754, rs8035855, rs10207567, rs1047891, rs4665972, rs13394343, rs67339103, rs17368443, rs4288924, rs1145074, and rs838142 ([@B62]). This GWAS also identified 11 common novel associations in *CUBN*, PRKCI, *EFNA3-EFNA1, MIR548AR-LOC646736, COL4A4, SPHKAP-PID1, INC01262-FRG1, RIB1-LINC00861*, and *BAHCC1* genes. UACR had previously been associated with another common variant in *SHROOM3* (rs17319721) in a meta-analysis of 31,580 and 27,746 Caucasian patients, although it did not reach GWA significance (*p*~discovery~ = 1.9 × 10^-6^) ([@B12]).

Although GWAS have successfully identified SNPs associations for the different traits associated with CKD, most of them are common DNA variants of small effect size. The proportion of phenotypic variance of eGFR explained by the 24 novel loci and the 29 previously identified by Pattaro et al. was 3.22%, therefore of limited help in CKD prediction ([@B113]).

An alternative to the concept of SNPs as single biomarkers is the use of PGRS, which provide individual estimates of the risk of presenting a determinate trait calculated from the combination of specific risks associated to SNPs. However, PGRS may provide only a partial solution in complex diseases. A recent analysis of 32 highly relevant traits related to five disease areas in 13,436 subjects of the Lifelines Cohort reported only 10.7% of the common-SNP heritability of these traits was explained by the different weighted PGRS, compiled from genome-wide significantly associated index SNPs based on previous GWAS ([@B109]). The percentage of variance explained by the PGRS for SCr, composed of three SNPs of high imputation quality (*R*^2^ \> 0.5) was 0.2% for both weighted and unweighted PGRS ([@B109]). Addition of one low-quality SNP increased the variance up to 0.21% (weighted PGRS). For the eGFR PGRS, composed of 33 SNPs (high-quality), the percentage of variance was 1.6% for unweighted PGRS and 1.8% for the weighted PGRS. Addition of 19 low-quality SNPs increased the variance up to 2.01% (weighted PGRS). There were no high-quality SNPs associated with UACR, so it was not possible to construct this PGRS. The inclusion of one low-quality SNP explained 0.12% of the variance with both weighted and unweighted PGRS ([@B109]). The PGRS for urate, composed of 20 SNPs (high-quality), explained from 2.0 to 4.2%, depending if either an unweighted or weighted PGRS was considered. Addition of eight low-quality SNPs increased the variance up to 4.52% (weighted PGRS) ([@B109]).

Next generation sequencing has an increasing role for both research and diagnosis of kidney disease. Recently, a NGS panel for a spectrum of genetic nephropathies, covering 301 genes, was designed and validated in a CLIA-approved laboratory ([@B85]). The assay showed excellent performance characteristics and was able to provide a specific molecular pathogenesis-based diagnosis in 46% of biopsies studied. An NGS panel covering all coding and regulatory regions of *UMOD* identified 119 genetic variants in 23 ESRD patients (compared to 22 controls without renal disease). Ninety of those variants were SNPs, 60 of them with minor allele frequency greater than 5%. Linkage disequilibrium allowed 20 SNPs to capture 100% of the alleles with a mean *R*^2^ of 0.97, providing a set of independent SNPs suitable for association analysis in larger cohorts ([@B6]).

Whole-exome sequencing provided a diagnosis in 22 out of 92 adults with CKD of unknown cause, familial nephropathy or hypertension (22/92; 24%) ([@B86]). The confirmation of the clinical diagnosis by WES allowed the appropriate genetic counseling and screening for the family members of some affected patients and helped in clarifying or entirely reclassified the disease in other cases ([@B86]). WES also identified *PARN* haploinsufficiency as a new genetic cause of CKD in this study ([@B86]). The *PARN* gene encodes a poly(A)-specific ribonuclease which mediates the post-transcriptional maturation of the telomerase RNA component (*TERC)* and causes telomere disorders ([@B104]). Exome sequencing has recently identified 11 loci (*p* \< 1 × 10^-4^) in eight genes (*PLEKHN1, NADK, RAD51AP2, RREB1, PEX6, GRM8, PRX, APOL1*) associated with T2DM-ESRD in 2476 cases and 2057 non-nephropathy control individuals of African American origin ([@B58]). However, exome data from 7974 self-identified healthy adults has recently demonstrated an implausibly high rate of candidate pathogenic variants for kidney and genitourinary diseases (1.4%), much higher than the prevalence of genetic renal/genitourinary disorders, even after stringent filtering criteria (removal of indels and minor allele frequency cutoffs of \< 0.01% and \<0.1% for dominant and recessive disorders, respectively) ([@B121]). This overestimation of potential pathogenic variants may increase the burden of uncertain diagnoses and medical referrals rather than alleviate it, therefore minimizing the utility of exome sequencing in clinical practice ([@B121]).

Mitochondria and Their Association With Chronic Kidney Disease
--------------------------------------------------------------

Mitochondria are organelles which generate ATP through OXPHOS and thus represent the primary energy source for normal function of the cell and body ([@B33]; [@B92]; [@B24]). The majority of mitochondrial proteins are encoded by nuclear genes ([@B152]; [@B42]). However, mitochondria also have their own circular genome 16,569 base pairs long that contains 37 genes which encode 13 proteins of the electron transport chain essential for OXPHOS ([@B102]) along with two rRNAs and 22 tRNAs ([@B144]; [@B33]; [@B57]). Mitochondrial dysfunction in kidney tissue may severely impact renal health and has previously been implicated in CKD development ([@B119]; [@B158]; [@B168]; [@B27]; [@B43]; [@B142]; [@B52]).

If mitochondrial metabolism is adversely affected by genetic variants it can result in kidney disease, sometimes as part of a wider clinical disorder ([@B119]). Somatic mtDNA mutations may be associated with aging, resulting in decline of mitochondrial function in older individuals ([@B158]). Increased levels of mtDNA mutations have previously been associated with several disorders including various forms of kidney disease ([Figure 2](#F2){ref-type="fig"}) ([@B158]).

![Increased mutation rate in mtDNA have previously been associated with several diseases including various forms of kidney disease. These mutations include point mutations, deletions and single nucleotide polymorphisms. Some of these mutations may result in several pathological phenotypes and these have been highlighted by a solid line between such genes.](fgene-10-00453-g002){#F2}

Mitochondrial dysfunction can occur via a number of pathways, for example persistent hyperglycemia (associated with diabetes) results in increased tubular oxygen consumption, and in turn leads to hypoxia of the kidney tissue ([@B63]). Mitochondrial dysfunction can be associated with increased electron leakage from the respiratory chain during OXPHOS, which results in ROS being generated which can cause kidney injury ([@B56]) including direct damage to DNA ([@B100]). Genetic variation in mtDNA ([Figure 2](#F2){ref-type="fig"}) or nuclear genes ([Figure 3](#F3){ref-type="fig"}) which influence mitochondrial function may impair respiratory chain complex activities leading to an increase in production of ROS resulting in a negative feedback loop, increasing mitochondrial dysfunction, OXPHOS defects and ROS generation along with a reduction in ATP production which leads to increased oxidative stress which may lead to uncontrolled autophagy, mitophagy, and further ROS production ([@B47]; [@B77]; [@B166]). Mitochondrial dysfunction, ROS generation and the resulting dysregulation of autophagic mechanisms may also lead to an upregulation of the intrinsic pathway of apoptosis which in turn leads to inflammation and fibrosis in the renal tubules and glomeruli ([@B145]; [@B139]; [@B165]; [@B34]).

![Genetic variation or altered expression of nuclear genes which encode mitochondrial proteins may impair respiratory chain complex activities leading to an increase in production of reactive oxygen species (ROS). This initiates a negative feedback loop, further reducing mitochondrial function, and ATP production along with an increase in OXPHOS defects and ROS generation leading to increased oxidative stress which may lead to uncontrolled autophagy, mitophagy and further ROS production. Mitochondrial dysfunction, ROS generation and the resulting dysregulation of autophagic mechanisms may also activate intrinsic apoptotic mechanisms resulting in inflammation and fibrosis in the renal tubules, glomerulus and podocytes eventually leading to kidney disease. Red arrows indicate underexpression and green arrows overexpression.](fgene-10-00453-g003){#F3}

Despite the mitochondrial genome being widely ignored in relation to CKD, a number of studies have identified mitochondrial genomic loci associated with specific forms of renal disease ([Table 1](#T1){ref-type="table"}). SNPs within *MT-HV2, MT-CO1*, and *MT-CO2c* have been associated with IgAN ([@B43]); the A3243G point mutation in the leucine^UUR^ tRNA gene (*MT-TL1*) was identified in patients with FSGS ([@B70]; [@B84]; [@B105]; [@B41]; [@B68]; [@B66]; [@B60]), other forms of renal disease ([@B60]) and in a male with a history of MELAS syndrome including kidney cancer, who rapidly developed renal failure after removal of the cancerous kidney ([@B117]). In general, mtDNA biomarkers have not been considered as potential biomarkers in association studies, therefore most findings concerning the mitochondrial genome in relation to CKD come from case reports. The *MT-TW* tRNA (m.5538 G \> A) mutation was identified as causing FSGS in a male ([@B91]). The (m.547 A \> T) and tRNA^Phe^ (m.616 T \> C) mutations were found in patients suffering from inherited tubulointerstitial kidney disease, who did not display typical symptoms of mitochondrial disease ([@B32]). A novel mutation in mtDNA (09155 A \> G) was described in a Caucasian female with a history of renal disease, and symptoms of Maternally inherited deafness and diabetes (MIDD) ([@B1]). Mutations in nuclear genes associated with mitochondrial function have also been associated with renal disease. The P99L mutation in the *BCS1L* gene was found in a female infant suffering from Neonatal Toni--Debré--Fanconi Syndrome, including renal tubulopathy ([@B45]). R45C and R56X mutations in the *BCS1L* gene were described in two siblings suffering from congenital lactic acidosis, including renal tubulopathy ([@B36]), and nine different mutations in *FBXL4* were identified in nine individuals suffering from mitochondrial encephalomyopathy including renal tubular acidosis ([@B51]).

###### 

Studies in mitochondrial genome and in nuclear genes associated with mitochondrial function (FSGS, focal segmental glomerulosclerosis; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MIDD, maternally inherited diabetes and deafness).

  Gene             Mutation                                                                                                                                                                                                                                                                   Disease                                                                     Methodology                                       Function                                                                 References
  ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------ ------------
  ?                09155 A \> G                                                                                                                                                                                                                                                               MIDD, renal disease                                                         Whole exome sequencing                            ?                                                                        [@B1]
  MT-TL1           3243 A \> G                                                                                                                                                                                                                                                                MELAS syndrome, renal cancer, renal failure                                 Restriction fragment length polymorphism (ApaI)   Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B117]
                                                                                                                                                                                                                                                                                              "Kidney disease"                                                            Allele-specific PCR                               Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B60]
                                                                                                                                                                                                                                                                                              FSGS                                                                        Restriction fragment length polymorphism (ApaI)   Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B84]
                                                                                                                                                                                                                                                                                              Kidney disease, diabetes, hearing loss                                      Restriction fragment length polymorphism (ApaI)   Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B70]
                                                                                                                                                                                                                                                                                              Kidney disease, diabetes, hearing loss, cataract                            Restriction fragment length polymorphism (ApaI)   Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B105]
                                                                                                                                                                                                                                                                                              FSGS, diabetes, hearing loss (3/4 cases), Cerebellar syndrome (1/4 cases)   Allele-specific amplification                     Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B41]
                                                                                                                                                                                                                                                                                              FSGS, diabetes (2/4 cases), hearing loss (1/4 cases)                        Restriction fragment length polymorphism (ApaI)   Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B68]
                                                                                                                                                                                                                                                                                              Renal disease, hearing loss                                                 ?                                                 Encodes tRNALeu(UUR), forms amino acids containing Leucine               [@B66]
  Control region   m.547 A \> T                                                                                                                                                                                                                                                               Inherited tubulointerstitial kidney disease                                 Sanger sequencing                                 ?                                                                        [@B32]
  MT-TF            m.616 T \> C                                                                                                                                                                                                                                                               Inherited tubulointerstitial kidney disease                                 Sanger sequencing                                 Encodes tRNA Phenylalanine, forms amino acids containing phenylalanine   [@B32]
  MT-TW            m.5538 G \> A                                                                                                                                                                                                                                                              FSGS                                                                        Whole exome sequencing                            Encodes tRNA tryptophan, forms amino acids containing tryptophan         [@B91]
  BCS1L            P99L                                                                                                                                                                                                                                                                       Neonatal Toni--Debré--Fanconi Syndrome, renal tubulopathy                   ?                                                 Assembly of mitochondrial respiratory chain complex III                  [@B45]
  BCS1L            R45C, R56X                                                                                                                                                                                                                                                                 Congenital lactic acidosis, renal tubulopathy                               Direct sequencing                                 Assembly of mitochondrial respiratory chain complex III                  [@B36]
  FBXL4            (c.1703G \> C \[p.Gly568Ala\], c.1444C \> T \[p.Arg482Trp\], c.1694A \> G (p.Asp565Gly), c.1652T \> A (p.Ile551Asn), c.1067del (p.Gly356Alafs^∗^15), c.1790A \> C (p.Gln597Pro), (c.\[614T \> C; 106A \> T\], p.\[Ile205Thr; Arg36^∗^\]), (c.1229C \> T \[p.Ser410Phe\])   Mitochondrial encephalomyopathy, renal tubular acidosis                     Whole exome sequencing                            Phosphorylation-dependent ubiquitination in mitochondria                 [@B51]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

Despite the limited published literature, the known significance of the mitochondrial genome with relation to renal function and the multiple case reports relating to individuals suffering from renal dysfunction associated with mutations in mitochondrial or mitochondrial-associated genes, suggest that there exists considerable potential for genetic mutations, resulting in mitochondrial dysfunction, to contribute toward CKD.

X and Y Chromosomes
-------------------

In CKD research, despite the efforts of extensive GWAS and other genomic analyses in this area, a "blind spot" still exists in the form of X- and Y-chromosome analysis. Fifty-three of the 3,643 publications found in the online GWAS catalog (hosted by the National Human Genome Research Institute-European Bioinformatics Institute) examined CKD and/or kidney-associated traits ([@B95]). Over 450 genome-wide associations (*p* \< 5 × 10^-8^) with renal disease and/or related traits were found at 140 loci across the genome ([Table 2](#T2){ref-type="table"}).

###### 

Comparison of associations reaching genome-wide significance (5 × 10^-8^) per chromosome in renal disease or related traits (bp, base pairs; Chr, chromosome; GWAS, genome-wide association studies).

  Chr   Size Chr (bp)   Coding Genes per Chr   Number of Associations with Renal Traits in GWAS Catalog   
  ----- --------------- ---------------------- ---------------------------------------------------------- ------------
  1     248956422       2050                   21                                                         15
  2     242193529       1301                   47                                                         12
  3     198295559       1079                   18                                                         8
  4     190214555       753                    25                                                         6
  5     181538259       884                    19                                                         7
  6     170805979       1045                   60                                                         11
  7     159345973       992                    26                                                         6
  8     145138636       1021                   16                                                         5
  9     138394717       778                    8                                                          3
  10    133797422       731                    14                                                         6
  11    135086622       1316                   33                                                         10
  12    133275309       1036                   26                                                         10
  13    114364328       321                    7                                                          3
  14    107043718       821                    1                                                          1
  15    101991189       616                    33                                                         8
  16    90338345        862                    29                                                         5
  17    83257441        1188                   24                                                         4
  18    80373285        269                    13                                                         5
  19    58617616        1474                   9                                                          4
  20    64444167        543                    9                                                          5
  21    46709983        232                    2                                                          1
  22    50818468        492                    8                                                          3
  X     156040895       846                    4                                                          2
  Y     57227415        63                     0                                                          0
                                               Total: 452                                                 Total: 140
                                                                                                          

As depicted in [Table 2](#T2){ref-type="table"}, the number of associations per chromosome is the lowest for chromosome Y (no associations) and the fourth lowest number of associations for chromosome X (four associations). This is not surprising for chromosome Y. Historically thought of as a "genetic wasteland" ([@B135]), association analyses usually exclude the Y-chromosome. Indeed, in the 53 studies examining renal disease/traits, only one included the Y-chromosome in the association analysis ([@B106]). Given that the Y-chromosome is the smallest and contains the fewest number of genes per number of base pairs ([@B167]), the lack of significant associations in this study is not unexpected.

However, for a chromosome of its size and gene content, the small number of associations found between X-chromosome SNPs and renal disease/traits raises questions as to why there are so few reported. Indeed, the only chromosomes with fewer reported associations are chromosomes 14 and 21, both of which are smaller and contain fewer genes than chromosome X. The lack of reported associations with sex chromosome SNPs could be due to a true lack of association or under-representation of sex chromosomes in GWAS.

Of the 53 GWAS in renal disease/traits, 10 are unclear as to whether X- and Y-chromosome SNPs were included in association analysis. Over half (62%) of the studies did not report sex chromosome association results, with many actively excluding the X- and Y-chromosomes from the association ([@B25]; [@B101]) or meta-analysis stages ([@B81]). Of the 10 studies (18%) that explicitly state that the X-chromosome analysis was included, only one study found associations between X-chromosome SNPs and renal traits (SCr and eGFR) that reached genome-wide significance ([@B72]). Two SNPS, rs12845465, and rs5987107, were both associated with SCr and eGFR (*p* \< 5 × 10^-8^). In only one study does Y-chromosome analysis appear to be included, where no SNPs reached genome-wide significance ([@B106]).

Therefore, with less than 20% of studies reporting X-chromosome results and Y-chromosome exclusion almost ubiquitous, it is not surprising that very few sex chromosome SNPs have shown association in studies of renal disease/traits. A possible explanation for sex chromosome exclusion is that traditional imputation methods call for the use of autosomes only ([@B99]). Even now that methods of X-chromosome imputation have been introduced ([@B98]; [@B79]), greater expertise is required and the X-chromosome is imputed separately from the autosomes, and these issues may lead some researchers to simply exclude it. The lack of reported analysis of X-chromosome SNPs in renal disease then leads to its exclusion from meta-analysis, as X-chromosome results are not common between all included studies. Poor genotyping of X-chromosome SNPs may also account for a reduced number of significant associations. Evidence has suggested that removal of X-chromosome SNPs during quality control is significantly more likely, due to a higher rate of chromosomal anomalies or missing call rate than autosomal SNPs ([@B162]). However, despite the successful imputation of the X-chromosome, chromosome Y lags behind. Despite recent efforts ([@B169]), haplogroup-based Y-chromosome imputation is still not widely used, with authors opting to instead use only directly genotyped SNPs ([@B26]).

The lack of sex chromosome inclusion in CKD GWAS may be one reason that the relationship between sex and CKD incidence/progression is so unclear. By regularly excluding these chromosomes from renal GWAS, we may miss SNPs that infer either increased CKD risk or protection to one gender in particular.

Traditionally, a greater risk of CKD incidence and progression to ESRD was associated with males. While current evidence still supports an increased rate of progression in men to ESRD ([@B164]), the risk inferred by gender on incidence of CKD is unclear. A study which used several definitions of incidence found that when using eGFR-based definitions of CKD (\<60 ml/min/1.73^2^), incident CKD was significantly higher in women than men (*p* = 0.02), but when using a minimum increase in SCr to detect CKD, men had a significantly higher incidence (*p* = 0.001) ([@B9]). Gender adjustment occurs in eGFR calculation, which may explain this difference. A study conducted to develop a CKD risk score also found that female sex was associated with prevalent CKD (*p* = 0.02) ([@B7]), as did a Turkish population study (*p* \< 0.001) ([@B140]). Additionally, a comprehensive review revealed that 38 studies found CKD was more prevalent in women, while 13 found it was more prevalent in men ([@B65]). Therefore, while women seem to make up a larger proportion of the individuals affected by CKD, affected men seem to progress at a much faster rate, highlighting the difference in the way that CKD affects men and women.

Clinical evidence and recent literature support a link between the sex chromosomes and impaired renal function. Arising as a result of a mutation in *COL4A5* on chromosome X, Alport syndrome is caused by impaired production or function of collagen in various basement membranes throughout the body, including in the glomerulus ([@B74]). The condition is characterized by hearing loss, ocular abnormalities and progression to ESRD, where up to 30% of women reach ESRD by age 60 ([@B130]) and the majority of affected males will require transplant or dialysis by their late twenties ([@B146]).

Discussion and Conclusion
=========================

Extensive efforts have been made to harness existing GWAS data and improve the sample size statistical power via GWAS meta-analyses to uncover true associations between genetic variants and CKD. Nevertheless, it remains challenging to explain all of the heritability of CKD with currently available methods and datasets.

The definition of CKD phenotype (based on SCr, eGFR and/or urinary albumin measurements) varies between published studies which impacts on the strength of genetic associations observed. CKD is phenotypically heterogeneous and CKD risk may be amplified by co-morbidities such as obesity. Many genetic studies have a cross-sectional case-control design with the determination of CKD based on a single measurements of kidney function. This limits the ability to explore dynamic gene-environment interactions over time, e.g., the impact of diet, gut microbiome, smoking, physical activity, stress, medication use or long-term glycemic control on genetic risk of developing CKD ([@B133]; [@B127]).

Prospective follow up of longitudinal cohorts at risk of developing CKD, such as the UK Biobank population may help to unravel some of the complex interplay of genetic background and environmental stressors contributing to kidney damage ([@B76]). Stratification by co-morbidity, e.g., elevated BMI in T2DM patients, may help identify additional risk variants with a stronger genetic predisposition to CKD ([@B114]).

The molecular biomarkers for CKD that have received less attention (telomeres, CNVs, mtDNA variants, X and Y chromosomes) are pieces of the missing heritability puzzle. Shorter telomere length is associated with renal dysfunction and CKD progression, even though reported results are conflicting. CNVs have been linked to CAKUT (1q23.1, 22q11, 4p16.1, 7q33, 8q13.2q13.3, and 17q12 regions), PUV (3p25.1p25.2 and 17p12), nephronophthisis (*NPHP1* gene) and IgAN (*DEFA1A3* locus). Information on mtDNA biomarkers is mostly from case reports, but the A3243G mutation in the *MT-TL1* gene has been associated with FSGS. One GWAS has found associations between X-chromosome SNPs and renal function (rs12845465 and rs5987107). No SNPs in the Y-chromosome have reached genome-wide significance.

Unraveling the missing heritability of CKD will need coherent integration of the different sources contributing to total heritability, and not just inclusion of missing gene variants. Using multiple --"omics" data by combining elements of the phenome, genome, epigenome, transcriptome, metabolome, proteome, and microbiome and translating these data into a useful individual CKD risk assessment remains a major challenge. These research goals efforts will likely help to increase our understanding of the mechanisms of kidney function and disease, and improve disease prediction.

Author Contributions
====================

MC-G, KA, RC, RS, LJS, AJM, and APM contributed to the conception or design of the work, acquisition, analysis and interpretation of data for the work, drafting the work and revising it critically for important intellectual content, provided the approval for publication of the content, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work has been partly funded by the Medical Research Council (Award Reference MC_PC_15025) and the Public Health Agency R&D Division (Award Reference STL/4760/13). MC-G and KA are funded by a Science Foundation Ireland-Department for the Economy (SFI-DfE) Investigator Program Partnership Award (15/IA/3152). LJS is the recipient of a postdoctoral research fellowship from the Northern Ireland Kidney Research Fund. RS and RC are funded by individual Ph.D. studentships from the Department for the Economy, Northern Ireland.

ATP

:   adenosine triphosphate

CAKUT

:   congenital anomalies of the kidney and urinary tract

CKD

:   chronic kidney disease

CKiD

:   chronic kidney disease in children cohort study

CNVs

:   copy number variants

CRISIS

:   chronic renal insufficiency standards implementation

DKD

:   diabetic kidney disease

eGFR

:   estimated glomerular filtration rate

ESRD

:   end-stage renal disease

FSGS

:   focal segmental glomerulosclerosis

GWAS

:   genome-wide association studies

IgAN

:   immunoglobulin A nephropathy

MMKD

:   mild to moderate kidney disease

mtDNA

:   mitochondrial DNA

NGS

:   next generation sequencing

NPH

:   nephronophthisis

OXPHOS

:   oxidative phosphorylation

PGRS

:   polygenic risk scores

PREVEND

:   Prevention of Renal and Vascular Endstage Disease study

PUV

:   posterior urethral valves

ROS

:   reactive oxygen species

SCr

:   serum creatinine

SNVs

:   single nucleotide variants

T2DM

:   type 2 diabetes mellitus

UACR

:   urinary albumin/creatinine ratio

WES

:   whole-exome sequencing
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